US Pharma MarketingAnalysts praise intismeran’s landmark Phase III win, look to further data
Analysts now turn to intismeran’s upcoming Phase II RCC readout, which they say could signal the drug’s wider potential across solid tumours.
Analysts now turn to intismeran’s upcoming Phase II RCC readout, which they say could signal the drug’s wider potential across solid tumours.
Source: Pharmaceutical Technology